GSK Pharmaceuticals’ stock jumped 5% following robust Q3 FY24 earnings, driven by strong revenue growth and expanding margins. As of 9:15 AM, the shares were trading 5.34% higher at Rs 2124.90
The company’s net profit before exceptional items and tax soared 34.7% year-on-year to ₹308.1 crore, compared to ₹228.7 crore in the same period last year.
Revenue climbed 17.9% YoY to ₹949.4 crore, reflecting sustained demand for its flagship brands. EBITDA surged 33.8% to ₹291.9 crore, while the EBITDA margin expanded to 30.7% from 27.1% in the previous year.
Key Growth Drivers:
- Core Brands Performance: Market-leading brands like Augmentin, Ceftum, and T-Bact continued to strengthen their positions.
- Respiratory Portfolio: Innovative therapies, including Nucala and Trelegy, witnessed strong adoption, improving patient access across India.
- Vaccines Business: GSK maintained its leadership in paediatric vaccines, while its adult vaccines segment gained traction, driven by Shingrix (Herpes Zoster Vaccine).
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
